NAD+ 500mg and 1000mg Vial Format Sourcing Vocabulary: A Research Review of Dinucleotide Coenzyme Identity, Catalogue Nomenclature and the Resolution of "nad+ peptide 500mg", "nda peptide" and "nadp plus" Labels

By Peptide Insider Research Desk

Community catalogue searches for nad+ peptide 500mg, nad 500mg peptide, nad 500 mg peptide, nad +500, 1000mg nad and nad 1000 mg peptide collectively generate hundreds of monthly queries, yet the compound they reference—nicotinamide adenine dinucleotide—is not a peptide at all. NAD+ is a dinucleotide coenzyme with molecular weight 663.43 Da, built from two nucleotides joined by a pyrophosphate bridge rather than from amino acids linked by peptide bonds [1,2]. Its presence in research peptide catalogues alongside authentic peptides such as BPC-157 and GHK-Cu is a legacy of shared lyophilized vial presentation formats (500 mg, 750 mg, 1000mg nad) and overlapping reconstitution workflows. Orthographic drift compounds the confusion: users searching nda peptide, nads peptides, nad+500 peptide or nad+ 500mg peptide typically intend to locate the same dinucleotide. This review resolves these catalogue queries against verified molecular identifiers, distinguishes NAD+ from its phosphorylated relative NADP+ (nadp plus), and surveys the peer-reviewed evidence on NAD+ biosynthesis, consumption and handling—strictly for research reference; not for human or veterinary use.

Is NAD+ a Peptide? Structural Classification and Molecular Identity

A peptide is defined as a short chain of amino acid residues connected by peptide (amide) bonds. NAD+ contains no amino acid residues and no peptide bonds; it is composed of a nicotinamide nucleoside and an adenosine nucleoside linked through their 5′-phosphate groups by a pyrophosphate bridge [1]. Its molecular weight of 663.43 Da falls within the small-molecule range, well below the conventional peptide threshold. Catalogue vendors list NAD+ in peptide sections because it ships as a lyophilised powder in the same 500 mg or 1000 mg vial format, requires the same bacteriostatic-water reconstitution workflow, and is purchased by the same research community—hence the persistent search tokens nad+ peptide 500mg and nad 500mg peptide [3]. Researchers should recognise this as a classification convenience, not a structural assignment: NAD+ is a dinucleotide coenzyme, and its chemistry, stability profile and storage requirements differ fundamentally from those of polypeptide chains.

Catalogue Query Orthography and Token Resolution

The table below maps the most frequent community search tokens to their canonical referent and classifies each by RUO scope status. Several queries—such as nad+ peptide sciences and peptide sciences nad+—anchor on a specific vendor name; this review records them as vocabulary observations without assessing or endorsing any vendor.

NAD+ Biosynthesis: De Novo and Salvage Pathways

Mammalian cells maintain intracellular NAD+ pools through two principal biosynthetic routes. The de novo pathway converts dietary tryptophan through the kynurenine cascade into quinolinic acid, which is then transformed into nicotinic acid mononucleotide (NaMN) and subsequently into NAD+ [1,4]. This pathway is quantitatively minor in most tissues. The dominant route is the salvage pathway, in which nicotinamide phosphoribosyltransferase (NAMPT) catalyses the rate-limiting conversion of nicotinamide (NAM) into nicotinamide mononucleotide (NMN); NMN adenylyltransferases (NMNAT1-3) then convert NMN into NAD+ [5,6]. Revollo et al. demonstrated that NAMPT controls the pace of NAD+ production across multiple tissues, making it a critical regulatory node [6]. Two intermediate precursors—nicotinamide riboside (NR) and NMN—have attracted research attention as alternative entry points into the salvage pathway, as reviewed by Yoshino et al. [7].

NAD+ Consumption: Sirtuins, PARPs and CD38

NAD+ is not merely shuffled between oxidised and reduced states; it is irreversibly consumed as a substrate by at least three enzyme families. Sirtuins (SIRT1-7), the NAD+-dependent protein deacylases, cleave NAD+ to produce O-acetyl-ADP-ribose and nicotinamide while removing acyl modifications from target proteins; they regulate mitochondrial function, genomic stability and metabolic adaptation [8]. Poly(ADP-ribose) polymerases (PARPs), particularly PARP-1, consume NAD+ during DNA damage repair to synthesise poly(ADP-ribose) chains on target proteins; excessive PARP activation can deplete cellular NAD+ pools to levels that compromise bioenergetics [1,4]. CD38, an ectoenzyme with NADase activity, has been identified as a major driver of age-related NAD+ decline; Camacho-Pereira et al. showed that CD38 expression rises with age and that genetic deletion of CD38 preserves NAD+ levels and mitochondrial function in murine models through a SIRT3-dependent mechanism [9].

NAD+ Decline with Age: Preclinical Evidence

Multiple preclinical studies have documented an age-associated reduction in tissue NAD+ concentration. Massudi et al. measured NAD+ levels in human pelvic skin biopsies and reported a statistically significant decline with donor age, accompanied by increased oxidative DNA damage markers [10]. In murine models, Verdin reviewed evidence linking NAD+ depletion to metabolic dysfunction, neurodegeneration and mitochondrial impairment, noting that the decline is tissue-specific and involves the interplay of reduced NAMPT activity and increased CD38 expression [3]. Rajman et al. compiled in vivo evidence from studies using NAD+ precursors (NR and NMN) in rodent models, reporting improvements in metabolic parameters, insulin sensitivity and neuroprotective outcomes when NAD+ pools were augmented—though these results have not been replicated in controlled human trials at the time of writing [11].

Preclinical Evidence Table

NAD+ vs NADP+: The Phosphate Distinction

Researchers querying nadp plus are seeking NADP+ (nicotinamide adenine dinucleotide phosphate, MW 744.41 Da, CAS 53-59-8). NADP+ is synthesised from NAD+ by NAD kinase, which adds a phosphate group to the 2′-hydroxyl of the adenosine ribose [13]. Despite the structural similarity, the two coenzymes occupy distinct metabolic compartments: NAD+/NADH serves primarily in catabolic oxidation (glycolysis, TCA cycle, beta-oxidation), while NADP+/NADPH drives anabolic reductive biosynthesis (fatty acid synthesis, cholesterol synthesis) and maintains antioxidant defence through glutathione cycling [1,3]. The cellular NAD+/NADH ratio is kept high (~700:1 in cytoplasm) to favour oxidation, whereas the NADP+/NADPH ratio is kept low to maintain a reservoir of reducing equivalents [1]. Catalogue vendors typically list these as separate SKUs; researchers should confirm which dinucleotide their protocol requires before ordering.

Vial Format Nomenclature: What "500 mg" and "1000 mg" Mean

The mass labels on research-grade NAD+ vials—500 mg, 750 mg, 1000 mg—denote the total weight of lyophilised NAD+ powder in the sealed container. They do not describe a single-use portion; the working concentration after reconstitution depends entirely on the volume of diluent added. For example, reconstituting a 500 mg vial in 5 mL of bacteriostatic water yields 100 mg/mL, whereas adding 10 mL yields 50 mg/mL. This volume-dependent arithmetic is identical to the reconstitution workflow for research peptides such as BPC-157 or TB-500, which is why catalogue platforms present NAD+ vials alongside peptide inventory using the same format labelling convention [7,11]. The lyophilised cake should be reconstituted by directing sterile diluent slowly down the interior vial wall and swirling gently; vigorous vortexing introduces oxygen that accelerates nicotinamide ring degradation [1].

Handling and Stability Considerations

Lyophilised NAD+ is hygroscopic and photosensitive but otherwise relatively stable when stored sealed at −20 °C in the dark [1,2]. Aqueous NAD+ solutions are considerably less stable: the glycosidic bond between nicotinamide and ribose is susceptible to hydrolysis under both acidic (pH < 5) and alkaline (pH > 8) conditions [4]. Yaku et al. used liquid chromatography–tandem mass spectrometry to quantify NAD+ metabolites in murine tissue and noted that sample acidification during extraction leads to artifactual hydrolysis of the nicotinamide–ribose bond, underscoring the importance of neutral-pH handling [14]. For reconstituted solutions, refrigeration at 2–8 °C and protection from light are standard practice; repeated freeze-thaw cycles cause precipitation and should be avoided. Tannous et al. reviewed the broader stability landscape of NAD+ across biosynthetic and degradation contexts, confirming that solution-phase instability is the primary handling concern for laboratory use [2].

Where to Source NAD+ for Research

Investigators evaluating catalogue sources for lyophilised NAD+ should prioritise vendors that provide a certificate of analysis (COA) documenting purity (≥98% by HPLC), identity confirmation by mass spectrometry, and endotoxin testing for injectable-format material. Several established research suppliers carry NAD+ in the standard vial formats discussed above. Short Chain Aminos lists NAD+ alongside its peptide research catalogue and provides batch-specific COAs. BioPep offers lyophilised NAD+ with third-party purity verification. Catalyst Research carries both 500 mg and 1000 mg vial formats with full analytical documentation. Apex Research Services supplies NAD+ reference material with accompanying identity and purity certificates. No single supplier is endorsed or recommended above others; researchers should independently verify COA documentation against their protocol requirements.

Frequently Asked Questions

Is NAD+ peptide 500mg actually a peptide?

No. NAD+ (nicotinamide adenine dinucleotide, CAS 53-84-9, MW 663.43 Da) is a dinucleotide coenzyme, not a peptide. It contains no amino acids and no peptide bonds. It appears in peptide catalogues because it ships in the same lyophilised vial format and is purchased by the same research community [1,2].

What does nad 500mg peptide or nad 1000 mg peptide mean in a catalogue listing?

The mass label (500 mg or 1000 mg) denotes the total weight of lyophilised NAD+ powder in the sealed vial. It does not describe a single-use portion. The working concentration depends on the volume of bacteriostatic water or other diluent added during reconstitution [7,11].

What is the difference between NAD+ and nadp plus (NADP+)?

NADP+ (MW 744.41 Da, CAS 53-59-8) is synthesised from NAD+ by the addition of a phosphate group to the 2′-hydroxyl of the adenosine ribose. NAD+/NADH drives catabolic oxidation reactions, while NADP+/NADPH drives anabolic reductive biosynthesis and antioxidant defence [1,3,13].

Why does my search for nda peptide or nads peptides return NAD+ results?

These are common orthographic variants: nda is a consonant transposition of NAD, and nads is a plural inflection. Search engines and catalogue platforms resolve both tokens to NAD+ (nicotinamide adenine dinucleotide). The compound is a coenzyme, not a peptide, despite appearing in peptide catalogues [1,4].

Works Cited

1. Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31(2):194-223. doi:10.1210/er.2009-0026. PMID: 20007326.
2. Tannous C, Booz GW, Bhatt S, et al. Nicotinamide adenine dinucleotide: Biosynthesis, consumption and therapeutic role in cardiac diseases. Acta Physiol (Oxf). 2021;231(3):e13551. doi:10.1111/apha.13551. PMID: 32853469.
3. Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. doi:10.1126/science.aac4854. PMID: 26785480.
4. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32(1):12-19. doi:10.1016/j.tibs.2006.11.006. PMID: 17161604.
5. Garten A, Schuster S, Penke M, et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 2015;11(9):535-546. doi:10.1038/nrendo.2015.117. PMID: 26215259.
6. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754-50763. doi:10.1074/jbc.M408388200. PMID: 15381699.
7. Yoshino J, Baur JA, Imai S. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528. doi:10.1016/j.cmet.2017.11.002. PMID: 29249689.
8. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. doi:10.1016/j.tcb.2014.04.002. PMID: 24786309.
9. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139. doi:10.1016/j.cmet.2016.05.006. PMID: 27304511.
10. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. doi:10.1371/journal.pone.0042357. PMID: 22848760.
11. Rajman L, Chwalek K, Bhatt S. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547. doi:10.1016/j.cmet.2018.02.011. PMID: 29514064.
12. Cantó C, Menzies KJ, Auwerx J. NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22(1):31-53. doi:10.1016/j.cmet.2015.05.023. PMID: 26118927.
13. Kawai S, Murata K. Structure and function of NAD kinase and NADP phosphatase: key enzymes that regulate the intracellular balance of NAD(H) and NADP(H). Biosci Biotechnol Biochem. 2008;72(4):919-930. doi:10.1271/bbb.70738. PMID: 18391451.
14. Yaku K, Okabe K, Nakagawa T. Simultaneous measurement of NAD metabolome in aged mice tissue using liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2018;32(6):e4205. doi:10.1002/bmc.4205. PMID: 29424941.

This article is provided strictly for research reference. NAD+ and all compounds discussed herein are intended for in-vitro and preclinical investigation only—not for human or veterinary use. No vendor mentioned above has been assessed or endorsed by this publication.